Stručni rad

https://doi.org/10.20471/acc.2018.57.04.17

Effect of Growth Hormone Therapy in Children with Prader-Willi Syndrome – Our First Experiences

Gordana Stipančić ; School of Dental Medicine, University of Zagreb, Zagreb, Croatia; Department of Pediatrics, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
Marija Požgaj Šepec ; Department of Pediatrics, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
Lavinia La Grasta Sabolić ; Department of Pediatrics, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia

Sažetak

Prader-Willi syndrome (PWS) is the most common cause of morbid obesity in childhood. It is the consequence of the lack of expression of genes on the paternally inherited 15q11.2-q13 region. Hyperphagia, obesity, short stature, psychomotor retardation and deterioration of behavior predominate in clinical presentation. Recombinant human growth hormone (rhGH) therapy, along with restriction of caloric intake, has become the mainstay in the management of PWS patients. Anthropometric parameters (height, body mass index (BMI)), therapy effect on carbohydrate and lipid metabolism, and occurrence of side effects were monitored in four children with PWS treated with rhGH for ³2 years at doses of up to 1 mg/m2/day. During the follow-up, the height standard deviation score (SDS) increased in comparison with baseline values, and after ³2 years of treatment with rhGH it was within the reference range for the general children population. BMI SDS decreased after the first year of treatment, but thereafter increased again; still, the level of BMI SDS was much better in comparison with most children with PWS of the same age and gender. RhGH therapy had no negative effect on glucose and lipid metabolism, nor caused any other adverse effect. Therapy including a customized diet for PWS, along with rhGH therapy, provided a satisfactory growth rate and prevented development of morbid obesity without side effects. This treatment approach would ensure transition of a greater number of PWS patients into adult care, where the multidisciplinary approach in care should be continued.

Ključne riječi

Prader-Willi syndrome; Obesity, morbid; Human growth hormone – therapeutic use; Paternal inheritance; Energy intake

Hrčak ID:

217847

URI

https://hrcak.srce.hr/217847

Datum izdavanja:

1.12.2018.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.848 *